Bioverativ´s Investigational BIVV009 Demonstrates Safety, Tolerability and Efficacy in Phase 1b Clinical Trial in Cold Agglutinin Disease (CAgD) Patients
(WorldNews Health)

- Phase 1b results achieve primary and secondary endpoints in CAgD cohort - Six of six primary CAgD patients had an increase in hemoglobin of 4 g/dl or more, and remainedtransfusion-free during treatment - Largest CAgD natural history study to date quantifies increased risk of thromboembolic events ATLANTA--(BUSINESS WIRE)--Dec. 11, 2017-- Bioverativ Inc.(NASDAQ: BIVV), a global biopharmaceutical company dedicated to transforming the lives of people with rare blood disorders, today presented data demonstrating that BIVV009, its first-in-class monoclonal antibody currently in Phase 3 clinical development for the treatment of cold agglutinin disease (CAgD), was generally well tolerated,...